hVIVO soars on trial success for universal influenza vaccination

hVIVO on Monday confirmed it has seen positive final results from its clinical trial of the safety and efficacy of two formulations and dosing regimens of FLU-v vaccine administered in healthy adults. The biopharma company said a single dose of FLU-v was shown to induce the strongest response rates, with this group experiencing a 60% reduction in confirmed influenza infections and an 83% reduction in the number of confirmed cases with severe symptoms compared to the placebo group. The results ...

Den vollständigen Artikel lesen ...